For hardworking American families who’ve watched children suffer while a medical system dithers, GeneDx’s push to end the so-called “diagnostic odyssey” is the kind of private-sector grit conservatives should cheer — not vilify. The company and its leaders, including Bryan Dechairo who joined GeneDx’s executive team in early 2025, are promising to turn what used […] More